Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. - Wikidata - awgldk - TriplyDB

Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.

Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.

http://www.wikidata.org/entity/Q34416693

about

LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications Structure-Based Design of Orally Bioavailable 1 H -Pyrrolo[3,2- c ]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.Kinase drug discovery--what's next in the field?A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases.Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor.Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission Dual leucine zipper kinase as a therapeutic target for neurodegenerative conditions.LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.Novel 2,4-dianilino-5-fluoropyrimidine derivatives possessing ALK inhibitory activities.Targeting LRRK2 in Parkinson's disease: an update on recent developments.Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor.Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover.Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2.Small-Molecule Inhibitors of LRRK2.The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.An integrated suite of modeling tools that empower scientists in structure- and property-based drug design.

P2860

Q24300605-63BC5038-88BC-4B4E-84DF-F2BC79485FD1 Q27013695-BE0AAE8D-88EF-4BE6-A7C1-B79498443CB4 Q27680652-D8C55608-B4F2-4875-8A98-C721327167F8 Q28078899-A703C557-9532-47EC-B7EF-F705FEEF12CC Q34325540-B47B4BFB-58A2-4DB1-A3E6-D9341BF6DEC8 Q34527876-C888B7F7-1B22-4ABC-AF80-8DFDFA5AF818 Q34764609-72075461-20D0-4FD6-847B-69002CDC8C3E Q35615188-4A47C3BC-2833-4901-A880-29BE7E4577FE Q37080018-956DE439-A1CC-407A-98F4-11EC6814B210 Q37595917-47DBEE80-F75B-4864-AAC2-BA87C834B711 Q38157047-146ABACE-E401-41A8-94EA-3D761E4BC474 Q38218398-C3A8E6EA-E2F2-45B3-BDDC-17D8E2543F2B Q38219430-CEBE340C-E055-4E4F-9580-E43510C4D478 Q38620229-61DCC4AC-B3B2-4C3D-901E-4D7DC383A495 Q38670162-9037A25C-F3D3-4E52-8ADE-6BA4810E23F2 Q38814476-8E22A78B-5D81-469C-B967-5E6B77BF4DE1 Q39078053-BCECBAA9-662F-4363-BD64-267E7A070460 Q39263032-3023F147-2785-436F-B618-AB09025AA124 Q39776744-F7C334AC-A31E-4EFB-85AF-006C63871BE1 Q42263195-26E6E070-3373-4390-A70C-75036DDB5629 Q46777308-BDE01C34-4805-4F0D-9B26-5AA9B54CFC7D Q47127108-6FEE9A12-F7F9-462E-92B3-D306A550C5FC Q48132251-215F4D64-DEC5-4328-BAEF-AF3B2FBB7B7E Q51082140-25B3CB26-4CFB-4292-BFEB-D391F45DDE0E Q51275277-53181D80-1307-49E7-B662-4680257FBA3B Q54275024-7ADD8B9E-E25C-4E29-AF59-ACEFF1BAD4EC

P2860

Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.

http://www.wikidata.org/entity/Q34416693

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Discovery of highly potent, se ...... K2) small molecule inhibitors.

@ast

Discovery of highly potent, se ...... K2) small molecule inhibitors.

@en

Discovery of highly potent, se ...... K2) small molecule inhibitors.

@nl

type

label

Discovery of highly potent, se ...... K2) small molecule inhibitors.

@ast

Discovery of highly potent, se ...... K2) small molecule inhibitors.

@en

Discovery of highly potent, se ...... K2) small molecule inhibitors.

@nl

prefLabel

Discovery of highly potent, se ...... K2) small molecule inhibitors.

@ast

Discovery of highly potent, se ...... K2) small molecule inhibitors.

@en

Discovery of highly potent, se ...... K2) small molecule inhibitors.

@nl

P1433

Q34416693-BF025FA8-322B-425B-B015-9A43E39750C0

P1476

Q34416693-4CEF39C1-8ACF-469B-A434-19B6C003156E

P2093

Q34416693-0509786F-72BC-4660-939C-6C8D298750A0

Q34416693-07136EE7-F5AE-445D-98D5-9F1813C65F11

Q34416693-1217E06D-C5BC-4942-855D-9472D7261A60

Q34416693-1EC1393F-40FD-49CC-BCDD-3E737DAA6B52

Q34416693-2B944FE7-0A79-4375-96D3-BA5703F7A2D9

Q34416693-367B4EEA-738E-4487-8458-073F41E0092B

Q34416693-38466712-85E3-4247-BD11-403AC6807B48

Q34416693-3B88F90D-3EA8-4E67-9396-91F93B0C4A8A

Q34416693-458AF0D2-19B3-4633-9C9A-B3464B4C2B79

Q34416693-4972EC94-247E-4C65-87A9-A03CE6F241CF

P304

Q34416693-5F8395FB-52EA-4745-AC4E-7FCEA153ECF7

P31

Q34416693-8FE77A9A-5D39-4FD7-B8B9-EBB9A2D482E6

P356

Q34416693-A021028A-D8A3-4ED8-8428-301E9E623D05

P407

Q34416693-ABB21DB5-F922-4353-B87F-3C22AA58B22C

P433

Q34416693-24B6D319-76E8-434C-9272-60419B033DD0

P478

Q34416693-A92EFD41-16F8-44D3-8FDD-3F13D3F47163

P577

Q34416693-5546C345-C1B3-4205-B80F-0E3DB99D5251

P698

Q34416693-29D78021-2938-4B2B-B860-8BBDF8BE6D89

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of highly potent, se ...... K2) small molecule inhibitors.

@en

P2093

Alan Beresford

http://www.w3.org/2001/XMLSchema#string

Andrew D Medhurst

http://www.w3.org/2001/XMLSchema#string

Andrew Gill

http://www.w3.org/2001/XMLSchema#string

Anthony A Estrada

http://www.w3.org/2001/XMLSchema#string

Antonio G DiPasquale

http://www.w3.org/2001/XMLSchema#string

Bryan K Chan

http://www.w3.org/2001/XMLSchema#string

Charles Baker-Glenn

http://www.w3.org/2001/XMLSchema#string

Claire E Le Pichon

http://www.w3.org/2001/XMLSchema#string

Daniel G Shore

http://www.w3.org/2001/XMLSchema#string

Daniel J Burdick

http://www.w3.org/2001/XMLSchema#string

P304

9416-9433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM301020Q

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22985112

http://www.w3.org/2001/XMLSchema#string